ALCL
MCID: ANP001
MIFTS: 62

Anaplastic Large Cell Lymphoma (ALCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 12 53 59 55 15 38 17
Anaplastic Large-Cell Lymphoma 37 29
Alcl 53 59
Cd30 Positive Anaplastic Large Cell Lymphoma 59
Ki-1 Positive Anaplastic Large Cell Lymphoma 59
Ki-1+ Anaplastic Large Cell Lymphoma 72
Primary Systemic Alcl 59
Sacl 59

Characteristics:

Orphanet epidemiological data:

59
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
KEGG 37 H01601
MESH via Orphanet 45 D017728
ICD10 via Orphanet 34 C84.6 C84.7
UMLS via Orphanet 73 C0206180
Orphanet 59 ORPHA98841
UMLS 72 C0206180

Summaries for Anaplastic Large Cell Lymphoma

NIH Rare Diseases : 53 Anaplastic large cell lymphoma (ALCL) is a rare type of Non-Hodgkins lymphoma. Lymphoma is a cancer of the lymph system, part of our immune system. Non-Hodgkins lymphoma involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells. Cancer cells in ALCL can be identified by their appearance under the microscope and by the presence of a tumor marker called CD30 or Ki-1. There are two types of ALCL, a type that affects mainly the skin (cutaneous ALCL) and a type that affects other body organs (systmic ALCL). Systemic ALCL also has two types, ALK-positive (anaplastic lymphoma kinase) and ALK-negative. ALK-positive ALCL occurs more often in children and young adults. ALK-negative ALCL tends to occur in older adults. The symptoms of cutaneous ALCL include red skin lesions that break open and do not heal. Sometimes cutaneous ALCL is also found in the lymph nodes. The symptoms of systemic ALCL include fever, night sweats, and weight loss (B symptoms). The cancer can be found in the bone, soft tissue, spleen, liver and skin. The cause of ALCL is unknown. One type of ALK-negative ALCL has been associated with breast implants. ALCL is diagnosed by a biopsy of the tumor or abnormal skin and examination of the tumor cells under a microscope. Additional testing including PET scans, CT scans, MRI and a bone marrow biopsy can tell doctors if the cancer has spread to other organs.[15060 ALCL is treated using chemotherapy, and a stem-cell transplant for people with more aggressive cancer or for ALCL that has come back. In addition, there are newer treatments that target the cancer cells directly and have been very effective. In general, ALK-positive ALCL has a better long-term outlook than ALK-negative ALCL.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as anaplastic large-cell lymphoma, is related to primary cutaneous anaplastic large cell lymphoma and alk-positive anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is LINC01013 (Long Intergenic Non-Protein Coding RNA 1013), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and b cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

KEGG : 37
Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by a proliferation of large lymphoid cells, referred to as hallmark cells, with strong expression of CD30. The World Health Organization recognizes 3 entities: primary cutaneous ALCL (pcALCL), anaplastic lymphoma kinase (ALK)-positive ALCL, and, provisionally, ALK-negative ALCL. pcALCL presents in the skin and, while it may involve locoregional lymph nodes, rarely disseminates. ALK-positive ALCL, by definition overexpresses an ALK-fusion gene, typically via t(2;5)(p23;35) which fuses the ALK gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in a NPM-ALK chimeric protein with constitutive tyrosine kinase activity. ALK-negative ALCLs lack ALK rearrangements and their genetic and clinical features are more variable. A subset of ALK-negative ALCLs has rearrangements at 6p25.3 involving DUSP22, a gene encoding a dual-specificity phosphatase that inhibits T-cell receptor signaling. DUSP22 rearrangements also are seen in a subset of pcALCLs.

Wikipedia : 75 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 370)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous anaplastic large cell lymphoma 34.1 PTPRC NPM1 MUC1 GZMB ALK
2 alk-positive anaplastic large cell lymphoma 34.1 STAT3 NPM1 MUC1 MCL1 JAK3 ALK
3 peripheral t-cell lymphoma 33.3 TNFRSF8 GZMB ALK
4 lymphoma 32.4 TNFRSF8 PAX5 NPM1 ALK
5 lymphomatoid papulosis 32.0 NPM1 GZMB ALK
6 reticulosarcoma 31.8 TNFRSF8 PTPRC PAX5 NPM1 MUC1 GZMB
7 histiocytosis 31.3 TNFRSF8 PTPRC CSF1R
8 lymphoma, hodgkin, classic 31.2 TNFSF8 PTPRC PAX5 ALK
9 mycosis fungoides 31.1 TNFRSF8 STAT3 GZMB CLU
10 inflammatory myofibroblastic tumor 31.1 RNF213 NPM1 ALK
11 myeloid sarcoma 30.6 PTPRC PAX5 NPM1
12 lung lymphoma 30.4 TNFRSF8 PAX5 GZMB ALK
13 mantle cell lymphoma 30.2 STAT3 PTPRC PAX5 MCL1
14 composite lymphoma 30.2 PAX5 GZMB
15 leukemia, acute myeloid 30.1 STAT3 PTPRC NPM1 MCL1 CSF1R
16 leukemia, chronic lymphocytic 29.9 TNFSF8 STAT3 PAX5 MCL1
17 sarcoidosis 1 29.5 TNFSF8 TNFRSF8 PTPRC IL9 ALK
18 lymphoma, non-hodgkin, familial 28.3 TRAF1 TNFSF8 TNFRSF8 PTPRC PAX5 NPM1
19 alk-negative anaplastic large cell lymphoma 13.0
20 anaplastic small cell lymphoma 11.9
21 b-cell lymphoma 10.7
22 lymphoproliferative syndrome 10.6
23 diffuse large b-cell lymphoma 10.6
24 rapidly involuting congenital hemangioma 10.6
25 cutaneous t cell lymphoma 10.5
26 hematopoietic stem cell transplantation 10.5
27 t-cell leukemia 10.5
28 leukemia, t-cell, chronic 10.5
29 adult t-cell leukemia 10.5
30 eccrine porocarcinoma 10.5 STAT3 MUC1
31 lymphocytic leukemia 10.5
32 hemophagocytic lymphohistiocytosis 10.5
33 conventional fibrosarcoma 10.4 TNFRSF8 PTPRC
34 neutropenia 10.4
35 severe combined immunodeficiency 10.4
36 t-cell non-hodgkin lymphoma 10.4
37 colon lymphoma 10.4 TNFRSF8 PTPRC ALK
38 t-cell lymphoma, subcutaneous panniculitis-like 10.4
39 neuropathy 10.4
40 acquired immunodeficiency syndrome 10.4
41 post-transplant lymphoproliferative disease 10.4
42 graft-versus-host disease 10.4
43 peripheral nervous system disease 10.4
44 breast lymphoma 10.4
45 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.4
46 malignant histiocytosis 10.4
47 hypereosinophilic syndrome 10.4
48 panniculitis 10.3
49 ichthyosis 10.3
50 dermatitis 10.3

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CD4 CSF1R IL9 JAK3 JUNB MCL1
2 immune system MP:0005387 10 CD4 CLU CSF1R IL9 JAK3 JUNB
3 endocrine/exocrine gland MP:0005379 9.97 ALK CD4 CSF1R JAK3 MCL1 PTPRC
4 neoplasm MP:0002006 9.43 ALK JUNB NPM1 PAX5 PTPRC STAT3
5 normal MP:0002873 9.23 CD4 CSF1R IL9 MCL1 PAX5 PTPRC

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Ifosfamide Approved Phase 4 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
5
Pirarubicin Investigational Phase 4 72496-41-4
6 HIV Protease Inhibitors Phase 4
7
protease inhibitors Phase 4
8 BB 1101 Phase 4
9
asparaginase Phase 4
10
Isophosphamide mustard Phase 4 0
11
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
12
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
13
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
14 Orange Approved Phase 3
15
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
16
Mercaptopurine Approved Phase 3 50-44-2 667490
17
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
20
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
21
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
22
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
25
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
26
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
27
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
28
Gemcitabine Approved Phase 3 95058-81-4 60750
29
Ondansetron Approved Phase 3 99614-02-5 4595
30
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
31
Morphine Approved, Investigational Phase 3 57-27-2 5288826
32
Dalteparin Approved Phase 3 9005-49-6
33
Ofloxacin Approved Phase 3 82419-36-1 4583
34
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
35
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
36
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
39
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
40
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
41
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
42
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
43
Histamine Approved, Investigational Phase 3 51-45-6 774
44
Cyproheptadine Approved Phase 3 129-03-3 2913
45
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
46
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
47
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
48 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
49 Antitubercular Agents Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
2 A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
3 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
4 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
5 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
7 International Protocol for the Treatment of Childhood Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
8 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
9 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
10 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
11 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
12 A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
13 A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
14 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
15 A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas Completed NCT00646854 Phase 3 CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab;CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
16 A Phase III Study of Involved Field Radiation Therapy (IFRT) in Patients With Histologically Aggressive Non-Hodgkin's Lymphoma Following High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) Completed NCT00031668 Phase 3
17 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
18 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
19 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
20 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
21 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
22 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
23 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
24 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
25 Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
26 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
27 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28 A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior To Autologous Stem Cell Transplant And Followed By Maintenance Rituximab Versus Observation Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
29 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
30 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
31 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
32 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
33 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
34 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
35 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
36 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
37 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Not yet recruiting NCT04021082 Phase 2, Phase 3 Cerdulatinib
38 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
39 Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas Unknown status NCT02274584 Phase 1, Phase 2
40 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophospahmid and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65 Unknown status NCT00785330 Phase 2 standard GVHD prophylaxis;rituximab
42 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43 A Phase II Trial of BBR 2778 in Combination With Cytarabine, Methylprednisolone and Cisplatin (BSHAP) as Salvage in Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
44 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
45 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
46 Phase II Study of Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed PTCL Unknown status NCT00840385 Phase 2 FAD
47 A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
48 A Phase II Study of 17-AAG in Patients With Relapsed/Refractory CD30+ Anaplastic Large Cell Lymphoma (ALCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL), and Relapsed/Refractory Classical Hodgkin's Lymphoma (HL) Completed NCT00117988 Phase 2 tanespimycin
49 A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL) Completed NCT00866047 Phase 2 brentuximab vedotin
50 A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children With Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma Completed NCT00939770 Phase 1, Phase 2 Crizotinib

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large-Cell Lymphoma 29

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

41
T Cells, Breast, B Cells, Bone, Skin, Bone Marrow, Lymph Node

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 3184)
# Title Authors PMID Year
1
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. 38 6
30596216 2019
2
Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. 38 6
29279550 2017
3
Anaplastic large cell lymphoma, ALK-negative. 38 6
22789917 2013
4
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. 9 38
20015877 2010
5
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. 9 38
20436485 2010
6
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. 9 38
20217288 2010
7
PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. 9 38
20118907 2010
8
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". 9 38
19695703 2010
9
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. 9 38
20179225 2010
10
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. 9 38
20406193 2010
11
Cytomorphologic features of primary anaplastic large cell lymphoma of the psoas muscle: a case report and literature review. 9 38
19760764 2010
12
Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. 9 38
19823169 2009
13
The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. 9 38
19734424 2009
14
The spectrum of peripheral T-cell lymphomas. 9 38
19509496 2009
15
Anaplastic lymphoma kinase: signalling in development and disease. 9 38
19459784 2009
16
Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. 9 38
19289586 2009
17
Frequent expression of CD99 in anaplastic large cell lymphoma: a clinicopathologic and immunohistochemical study of 160 cases. 9 38
19289593 2009
18
Expression of ALK protein, mRNA and fusion transcripts in anaplastic large cell lymphoma. 9 38
19135051 2009
19
Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants. 9 38
19220628 2009
20
Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. 9 38
19760074 2009
21
Primary leptomeningeal ALK+ lymphoma in a 13-year-old child. 9 38
19131793 2008
22
A rapidly progressing, fatal case of primary systemic anaplastic large cell lymphoma presenting as erythroderma--association with carbamazepine. 9 38
19265618 2008
23
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. 9 38
18974134 2008
24
[Study on activation of AKT/mTOR pathway in anaplastic large cell lymphoma]. 9 38
19176054 2008
25
Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. 9 38
18509351 2008
26
[Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis]. 9 38
18549625 2008
27
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. 9 38
18519761 2008
28
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. 9 38
18451166 2008
29
[Nuclear microarray combined with fluorescence in situ hybridization for detecting ALK gene translocation in paraffin-embedded anaplastic large cell lymphoma and its significance]. 9 38
18495593 2008
30
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. 9 38
18324919 2008
31
Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. 9 38
18275429 2008
32
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. 9 38
18187570 2008
33
Pathobiology and molecular profiling of peripheral T-cell lymphomas. 9 38
19074096 2008
34
Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. 9 38
17320171 2008
35
Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. 9 38
17965727 2008
36
Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma. 9 38
17655697 2007
37
Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. 9 38
17608768 2007
38
Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. 9 38
17560012 2007
39
Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. 9 38
17610208 2007
40
Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. 9 38
17490616 2007
41
Expression of anaplastic lymphoma kinase, tyrosine-phosphorylated STAT3, and associated factors in pediatric anaplastic large cell lymphoma: A report from the children's oncology group. 9 38
17439836 2007
42
Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. 9 38
17488159 2007
43
c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. 9 38
17325487 2007
44
Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. 9 38
17321986 2007
45
Identification and validation of the anaplastic large cell lymphoma signature. 9 38
17695725 2007
46
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. 9 38
17157164 2006
47
JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. 9 38
16939498 2006
48
Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene. 9 38
16984614 2006
49
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. 9 38
16871283 2006
50
Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. 9 38
16648862 2006

Variations for Anaplastic Large Cell Lymphoma

Cosmic variations for Anaplastic Large Cell Lymphoma:

9 (show all 44)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM45929 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.408A>C p.Q136H 17:7675204-7675204 8
2 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 8
3 COSM43989 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.596G>A p.G199E 17:7674935-7674935 8
4 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 8
5 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 8
6 COSM10813 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.394A>G p.K132E 17:7675218-7675218 8
7 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 8
8 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 8
9 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 8
10 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 8
11 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 8
12 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 8
13 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 8
14 COSM1155739 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.1981G>T p.D661Y 17:42322402-42322402 8
15 COSM1155745 STAT3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.1981G>C p.D661H 17:42322402-42322402 8
16 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 8
17 COSM6987010 SPEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.92G>A p.R31H 1:15872824-15872824 8
18 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 8
19 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 8
20 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 8
21 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 8
22 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 8
23 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 8
24 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 8
25 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 8
26 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.181C>A p.Q61K 1:114713909-114713909 8
27 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 8
28 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 8
29 COSM6987011 CCND1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.505C>G p.P169A 11:69643922-69643922 8
30 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 8
31 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 8
32 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 8
33 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 8
34 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 8
35 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 8
36 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 8
37 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 8
38 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 8
39 COSM6987012 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.505C>G p.P169A 11:69643922-69643922 8
40 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 8
41 COSM7335402 SF3B1 soft tissue,liver,other,neoplasm c.2014G>T p.A672S 2:197402619-197402619 3
42 COSM7335401 NCOR1 soft tissue,liver,other,neoplasm c.3838G>T p.G1280W 17:16072202-16072202 3
43 COSM7335404 MSH6 soft tissue,liver,other,neoplasm c.3215G>A p.G1072D 2:47803462-47803462 3
44 COSM7335403 MAP2K2 soft tissue,liver,other,neoplasm c.979A>G p.N327D 19:4097284-4097284 3

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TNFSF8 TNFRSF8 STAT3 RNF213 PTPRC MUC1
2
Show member pathways
13.75 TNFSF8 TNFRSF8 STAT3 MUC1 JUNB JAK3
3
Show member pathways
13.17 TNFSF8 TNFRSF8 STAT3 JUNB JAK3 IL9
4
Show member pathways
12.96 TNFSF8 TNFRSF8 STAT3 MUC1 MCL1 JUNB
5
Show member pathways
12.8 STAT3 PTPRC JUNB JAK3 CD4
6 12.66 TRAF1 TFG STAT3 JAK3 CSF1R ALK
7
Show member pathways
12.57 TRAF1 STAT3 MCL1 JAK3 CD4
8
Show member pathways
12.16 STAT3 PTPRC MCL1 JAK3 IL9 CSF1R
9 12.14 TRAF1 PAX5 GZMB CSF1R
10
Show member pathways
11.91 STAT3 JUNB JAK3 CD4
11
Show member pathways
11.85 STAT3 GZMB CD4
12 11.74 TRAF1 TNFRSF8 STAT3 PTPRC PAX5 JUNB
13
Show member pathways
11.72 STAT3 MCL1 JUNB
14 11.72 STAT3 PTPRC JAK3 CSF1R
15 11.71 STAT3 MUC1 MCL1 JUNB JAK3
16 11.67 PAX5 CSF1R CD4
17 11.66 STAT3 PTPRC CD4
18 11.64 PTPRC CSF1R CD4
19 11.61 PTPRC IL9 GZMB CD4
20 11.4 JAK3 IL9 CD4
21
Show member pathways
11.39 STAT3 JAK3 IL9
22
Show member pathways
11.34 STAT3 JAK3 CSF1R
23 11.3 STAT3 PTPRC JAK3
24 11.25 PTPRC JAK3 CD4
25 11.08 TNFRSF8 STAT3 PTPRC PAX5 CD4

GO Terms for Anaplastic Large Cell Lymphoma

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.87 STAT3 NPM1 MCL1 CSF1R
2 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.73 CSF1R CD4 ALK
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.69 PTPRC CSF1R CD4
4 positive regulation of T cell proliferation GO:0042102 9.58 PTPRC JAK3 CD4
5 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.55 PTPRC CD4
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.54 STAT3 JAK3
7 response to cytokine GO:0034097 9.54 STAT3 MCL1 JUNB
8 regulation of JAK-STAT cascade GO:0046425 9.49 PTPRC JAK3
9 interleukin-21-mediated signaling pathway GO:0038114 9.46 STAT3 JAK3
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 TRAF1 NPM1 CLU ALK
11 enzyme linked receptor protein signaling pathway GO:0007167 9.43 JAK3 CD4
12 interleukin-15-mediated signaling pathway GO:0035723 9.43 STAT3 JAK3 CD4
13 regulation of extrinsic apoptotic signaling pathway GO:2001236 9.32 TRAF1 PTPRC
14 regulation of B cell receptor signaling pathway GO:0050855 9.18 PAX5
15 cytokine-mediated signaling pathway GO:0019221 9.17 STAT3 MUC1 MCL1 JUNB JAK3 CSF1R
16 interleukin-9-mediated signaling pathway GO:0038113 9.13 STAT3 JAK3 IL9
17 signal transduction GO:0007165 10.13 TRAF1 TNFSF8 TNFRSF8 STAT3 NPM1 CSF1R

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.43 STAT3 PTPRC NPM1 MCL1 CSF1R CD4
2 protein phosphatase binding GO:0019903 9.33 STAT3 JAK3 CSF1R
3 transmembrane signaling receptor activity GO:0004888 8.62 TNFRSF8 CD4

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....